GPR35 receptor novel agonist and application thereof
An agonist and receptor technology, applied in the field of targeting active molecules and their applications, can solve the problems of single structure and low activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0030] Example 1: Construction of GPR35 receptor screening model
[0031] Materials Minbutanol and ML145 were purchased from Sigma; natural compounds were purchased from Shanghai Yuanye Biotechnology Co., Ltd., and CHO-hGPR35 cells were obtained by transfection and screening by our company. The detection platform is the third generation of Corning Imager, the detected signal is the wavelength shift caused by cell dynamic mass reset (DMR).
[0032] The agonistic probe of GPR35 receptor is gentianol, and the antagonistic probe is ML145. Firstly, based on the unlabeled cell integrated pharmacology technology, the present invention uses the probes Protonne and ML145 on CHO-hGPR35 cells to establish models for agonism analysis, desensitization analysis and antagonism analysis, laying the foundation for subsequent screening of natural compounds. The CHO-hGPR35 cells in the logarithmic growth phase were inoculated in different wells of a 384-well cell plate, the inoculation volume...
Embodiment 2
[0033] Example 2: Preliminary screening of natural compounds on the GPR35 receptor model
[0034] The CHO-hGPR35 cells in the logarithmic growth phase were inoculated in different wells of a 384-well cell plate, the inoculation volume of each well was 40 μL, and the number of cells inoculated in each well was 1×10 4 First, the inoculated cell plate was placed in a cell culture incubator for 24 h and then the experiment was carried out. Firstly, monitor the response signal of the compound to be screened (final concentration is 100 μM) acting on CHO-hGPR35 cells; Influence of the response signal on the cell.
[0035] All compounds acted on CHO-hGPR35 cells at a final concentration of 100 μM, and the resulting DMR response signal intensity is shown in figure 2 A; After compound pretreatment of CHO-hGPR35 cells for 1h, the DMR response signal intensity of adding 200nM fentanil is shown in figure 2 b. According to the basis for the judgment of new GPR35 receptor agonists - th...
Embodiment 3
[0036] Example 3: Validation of target specificity of active compounds
[0037] by comparison figure 2 A and 2B, it is inferred that the above compounds have an agonistic effect on the GPR35 receptor, but the target specificity of these compounds needs further verification. Compounds with agonistic activity need to use GPR35-specific antagonist ML145 to verify whether the generated DMR signal can be inhibited, so as to determine whether it is GPR35-specific agonism.
[0038] The CHO-hGPR35 cells in the logarithmic growth phase were inoculated in different wells of a 384-well cell plate, the inoculation volume of each well was 40 μL, and the number of cells inoculated in each well was 1×10 4 First, the inoculated cell plate was placed in a cell culture incubator for 24 h and then the experiment was carried out. First, the agonistic and desensitizing effects of the above 38 compounds were repeatedly verified, and then CHO-hGPR35 cells were treated with ML145 (final concentrat...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com